C Blatrix
About
In The Last Decade
C Blatrix
36 papers receiving 250 citations
Peers
Comparison fields: 5 of 74
- Hematology 141
- Genetics 53
- Molecular Biology 51
- Pulmonary and Respiratory Medicine 41
- Cardiology and Cardiovascular Medicine 38
Countries citing papers authored by C Blatrix
This map shows the geographic impact of C Blatrix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Blatrix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Blatrix more than expected).
Fields of papers citing papers by C Blatrix
This network shows the impact of papers produced by C Blatrix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Blatrix. The network helps show where C Blatrix may publish in the future.
Co-authorship network of co-authors of C Blatrix
This figure shows the co-authorship network connecting the top 25 collaborators of C Blatrix. A scholar is included among the top collaborators of C Blatrix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Blatrix. C Blatrix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [Prolonged bleeding time under the influence of certain drugs]. | 1 |
| 2 | [Sinus bradycardia and sinoauricular block induced by carbamazepine]. | 3 |
| 3 | [Post-radiation meningioma. A late complication of the irradiation of the sella turcica]. | 5 |
| 4 | 7 | |
| 5 | 4 | |
| 6 | Clinical pharmacology studies with acenocoumarol. | 1 |
| 7 | [The use of new immunoglobulin preparation, enriched in IgA and IgM (IgGAM)]. | 2 |
| 8 | 8 | |
| 9 | 6 | |
| 10 | [Special preparation of intravenously injectable gamma globulin]. | 2 |
| 11 | 1 | |
| 12 | Preparation and clinical use of P.P.S.B. (factors II, VII, X and IX concentrate). | 16 |
| 13 | 40 | |
| 14 | [Antiplasmin, antitrypsin and antithrombin activity of alpha-2-macroglobulin]. | 5 |
| 15 | [Clinical and biological aspects of some vitamin K antagonists]. | 1 |
| 16 | 5 | |
| 17 | [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. | 9 |
| 18 | [A circulating anticoagulant inhibiting the first stage of coagulation]. | 1 |
| 19 | [Treatment of hemophilia A by coagulant fractions (fractions I-A and I-F)]. | 2 |
| 20 | [Renal papillary necrosis in diabetes]. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.